MedTrace Logo

A Study of High Dose MHAA4549A in Healthy Volunteers

NCT02284607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-03-09

No results posted yet for this study

Summary

This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of two, single intravenous (IV) high doses of MHAA4549A as compared to placebo when administered to healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

DRUG

MHAA4549A

MHAA4549A single, intravenous dose administration, lower dose level

DRUG

MHAA4549A

MHAA4549A single, intravenous dose administration, higher dose level

DRUG

Placebo

Matching placebo to MHAA4549A administration

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-03
Primary Completion
2015-03-13
Completion
2015-03-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02284607 on ClinicalTrials.gov